The weighty issue of Ozempic

Ozempic, designed for type-2 diabetes treatment, has garnered
widespread attention for its potential to aid weight loss in obese
individuals. In Australia, where obesity affects 30% of the
population, it has sparked significant interest and Novo Nordisk,
the company behind it, has seen its share price surge by almost
500% in 5 years. While there are other similar drugs on the market,
Ozempic is the OG. Which is why we are delving into it for News
Club... Club Picks: This podcast on ABC Radio National’s Life
Matters program includes an interview with podcaster Claire Murphy.
S The invention of these drugs has had - and will continue to have
- economic impacts. This episode of The Economist’s Money Talks
podcast goes through that, and the industry that’s booming off the
back of them.  You can’t go far in this discussion without
mentioning Oprah Winfrey… The US multi-media legend has had a
decades-long struggle with her weight. She’s even made a show about
it - Shame, Blame and the Weight Loss Revolution - a clip is
here.  Hosts: Claire Kimball & Kate Watson Producer:
Annelise Taylor